Work

Preclinical and clinical studies of a class I/IV HDAC inhibitor, mocetinostat, in melanoma.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.10052

Authors: Jeffrey S. Weber, Andressa S Laino, Melinda Vassallo, Anna Pavlick, Saundra Malatyali, Swathi Krishnarajapet, Gabriel DeLeon, Isan Chen, Max Hallin, David Woods

Institutions: NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Mirati Therapeutics (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3029110601

Cites:

Cited by: 9

Related to: 10